A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The clinical significance of low to low-normal testosterone (T) levels in men remains debated. AIM: To analyze the effects of raising serum T on lean body mass (LBM), fat mass (FM), total body mass, and health-related quality-of-life (HRQoL). METHODS: Randomized, double-blind, placebo-controlled study. Men, aged 50-80 years, with serum total T<15 nmol/L and bioavailable T < 6.68 nmol/L, and a Aging Males' Symptoms (AMS) total score >36, received 6 months treatment with transdermal 1% T gel (5-7.5 mg/day; n =183) or placebo gel (n =179), followed by 12 months open-label with T in all. RESULTS: After 6 months, LBM increased in T- treated patients by 1.28 ± 0.15 kg (mean ± SE) and FM decreased by 1.16 ± 0.16 kg, with minor changes with placebo (LBM +0.02 ± 0.10 kg and FM -0.14 ± 0.12 kg; all p < 0.001, T group vs. placebo). Changes were largely similar across subgroups of age, baseline total testosterone, and baseline BMI. Total HRQoL improved compared with placebo (p < 0.05, T group vs. placebo). CONCLUSIONS: Six months 1% T gel improved body composition and HRQoL in symptomatic men with low to low-normal T, with further improvements over the following 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“by using the total testosterone, the levels of sex hormone binding globulin and of albumin [19].”
MethodBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 14×
“However, there is no generally accepted lower-limit-ofnormal for serum testosterone for testosterone deficiency in older men, and a cross-sectional cohort study in men aged 50–86 years has shown that symptoms and metabolic risk factors associated with LOH accumulate as total testosterone levels fall below 15 nmol/L [1…”
BackgroundInfluentialInvestigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Self-citationKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
Srikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 3×
“For instance, one widely cited clinical study indicated that androgen deficiency affected approximately 39% of men aged ≥45 years reporting to primary care centers in the USA [6], while large epidemiological studies find much lower prevalence rates, with a prevalence rate of only 2.”
BackgroundInfluentialWang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566 · cited 1×
“[14], or in open-label studies [24,25] using parenteral testosterone.”
BackgroundAssociation of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Sex hormones, inflammation and the metabolic syndrome: a population-based study
Laaksonen, D., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T., Salonen, R., Rauramaa, R., & Salonen, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490601 · Cited by 438
Boyanov, M. A., Boneva, Z., & Christov, V. G. (2003) · The Aging Male · doi:10.1080/tam.6.1.1.7 · Cited by 381
Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007005 · Cited by 349
Self-citationAndrogen Treatment of Abdominally Obese Men
Mårin, P., Holmtäng, S., Gustafsson, C., Jönsson, ‡., Kvist, ‡., Elander, A., Eldh, J., Sjöström, L., Holm, G., & Björntorp, P. (1993) · Obesity Research · doi:10.1002/j.1550-8528.1993.tb00618.x · Cited by 345
Tajar, A., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Bartfai, G., Boonen, S., Casanueva, F. F. F., Forti, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2513 · Cited by 318 · cited 13×
“However, there is no generally accepted lower-limit-ofnormal for serum testosterone for testosterone deficiency in older men, and a cross-sectional cohort study in men aged 50–86 years has shown that symptoms and metabolic risk factors associated with LOH accumulate as total testosterone levels fall below 15 nmol/L [1…”
BackgroundInfluentialAndrogens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Allan, C. A., Strauss, B. J. G., Burger, H. G., Forbes, E. A., & McLachlan, R. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1291 · Cited by 298
Onset of effects of testosterone treatment and time span until maximum effects are achieved
Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0221 · Cited by 232 · cited 1×
“The present study was relatively short and did not allow to observe the potential benefits of the intervention on variables other than body composition [26,27].”
BackgroundSelf-citationThe Aging Males’ Symptoms (AMS) scale: update and compilation of international versions
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-15 · Cited by 186
Kim, T. N., Park, M. S., Lim, K. I., Yang, S. J., Yoo, H. J., Kang, H. J., Song, W., Seo, J. A., Kim, S. G., Kim, N. H., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.06.013 · Cited by 167 · cited 1×
“However, the primary endpoint of this study, LBM, is probably a highly relevant variable modifying the long-term risk of insulin resistance and metabolic syndrome [43,44].”
BackgroundLiu, P. Y., Beilin, J., Meier, C., Nguyen, T. V., Center, J. R., Leedman, P. J., Seibel, M. J., Eisman, J. A., & Handelsman, D. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0862 · Cited by 142
Saad, F., Gooren, L., Haider, A., & Yassin, A. (2008) · Andrologia · doi:10.1111/j.1439-0272.2008.00807.x · Cited by 89 · cited 1×
“reported that increments in testosterone predicted treatment effects [33].”
BackgroundSelf-citationHaider, A., Gooren, L. J. G., Padungtod, P., & Saad, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1202774 · Cited by 83 · cited 1×
“[14], or in open-label studies [24,25] using parenteral testosterone.”
BackgroundSelf-citationAnawalt, B. D., Hotaling, J. M., Walsh, T. J., & Matsumoto, A. M. (2012) · Journal of Urology · doi:10.1016/j.juro.2011.11.095 · Cited by 55
Cited by
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men
Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S., Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015) · The Aging Male · doi:10.3109/13685538.2015.1004049 · Cited by 312
Self-citationCorona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297
Testosterone supplementation and sexual function: A meta-analysis study
Corona, G., Isidori, A. M., Buvat, J., Aversa, A., Rastrelli, G., Hackett, G., Rochira, V., Sforza, A., Lenzi, A., Mannucci, E., et al. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12536 · Cited by 263
Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies
Corona, G., Rastrelli, G., Di Pasquale, G., Sforza, A., Mannucci, E., & Maggi, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.04.641 · Cited by 138
Metadata
- Authors
- Behre, H. M., Tammela, T. L. J., Arver, S., Tolrá, J. R., Bonifacio, V., Lamche, M., Kelly, J., Hiemeyer, F., for the European Testogel® Study Team, Giltay, E. J., & Gooren, L. J.
- Venue
- The Aging Male
- Publisher
- Informa UK Limited
- Published
- 2012-07-26
- Volume
- 15
- Issue
- 4
- Pages
- 198-207
- ISSN
- 1368-5538 (ISSN-L)
- 1473-0790
- OpenAlex
- W2108362230
- Cited by
- 109
- References
- 24
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.